JP2021535749A - ワクチン組成物を調製するためのプロセス - Google Patents

ワクチン組成物を調製するためのプロセス Download PDF

Info

Publication number
JP2021535749A
JP2021535749A JP2021512906A JP2021512906A JP2021535749A JP 2021535749 A JP2021535749 A JP 2021535749A JP 2021512906 A JP2021512906 A JP 2021512906A JP 2021512906 A JP2021512906 A JP 2021512906A JP 2021535749 A JP2021535749 A JP 2021535749A
Authority
JP
Japan
Prior art keywords
peptide
cancer
subject
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535749A5 (cg-RX-API-DMAC7.html
Inventor
リシエヴィッチ、ジュリアナ
モルナー、レヴェンテ
トゥケ、エニク
トート、ヨージェフ
ロリンツ、オルショヤ
シゾヴスキー、ゾルト
ソモギー、エステル
パンヤ、カタリン
メジェシ、モニカ
パーレシュ、ピーテル
Original Assignee
トレオス バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレオス バイオ リミテッド filed Critical トレオス バイオ リミテッド
Publication of JP2021535749A publication Critical patent/JP2021535749A/ja
Publication of JP2021535749A5 publication Critical patent/JP2021535749A5/ja
Priority to JP2025019485A priority Critical patent/JP2025069437A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021512906A 2018-09-04 2019-09-03 ワクチン組成物を調製するためのプロセス Pending JP2021535749A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019485A JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine
GB1814362.8 2018-09-04
PCT/EP2019/073481 WO2020048995A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019485A Division JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Publications (2)

Publication Number Publication Date
JP2021535749A true JP2021535749A (ja) 2021-12-23
JP2021535749A5 JP2021535749A5 (cg-RX-API-DMAC7.html) 2022-11-28

Family

ID=63920945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512906A Pending JP2021535749A (ja) 2018-09-04 2019-09-03 ワクチン組成物を調製するためのプロセス
JP2025019485A Pending JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019485A Pending JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Country Status (17)

Country Link
US (3) US20200069786A1 (cg-RX-API-DMAC7.html)
EP (1) EP3847185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021535749A (cg-RX-API-DMAC7.html)
KR (1) KR20210086610A (cg-RX-API-DMAC7.html)
CN (1) CN113383009A (cg-RX-API-DMAC7.html)
AU (1) AU2019334261B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110923A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000534A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004028A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190669A1 (cg-RX-API-DMAC7.html)
GB (1) GB201814362D0 (cg-RX-API-DMAC7.html)
IL (1) IL281220A (cg-RX-API-DMAC7.html)
MA (1) MA53544A (cg-RX-API-DMAC7.html)
MX (1) MX2021002543A (cg-RX-API-DMAC7.html)
SG (1) SG11202101881UA (cg-RX-API-DMAC7.html)
WO (1) WO2020048995A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
MX2022001206A (es) * 2019-07-30 2022-05-03 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP3945320A1 (en) * 2020-07-29 2022-02-02 Corporació Sanitària Parc Taulí Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
EP4236981A1 (en) * 2020-10-28 2023-09-06 Follicum AB Peptides for use in skin and hair pigmentation
KR20240007162A (ko) * 2021-04-14 2024-01-16 티스캔 테라퓨틱스, 인크. Magec2 면역원성 펩티드, magec2 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN114195861A (zh) * 2022-01-05 2022-03-18 许昌学院 亲和肽
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
CN115785211B (zh) * 2022-06-10 2024-09-24 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用
WO2026125390A1 (en) 2024-12-09 2026-06-18 Vib Vzw Fthl17 immunogen and tcr

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039716A1 (en) * 2005-10-01 2007-04-12 Cancer Research Technology Ltd T cell epitopes from the 5t4 tumor associated antigen and their use in treatment of cancer
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039716A1 (en) * 2005-10-01 2007-04-12 Cancer Research Technology Ltd T cell epitopes from the 5t4 tumor associated antigen and their use in treatment of cancer
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
がん免疫療法のメカニズム解明と臨床への展開 がんと免疫, vol. 1版, JPN6022004948, 2015, pages 176 - 185, ISSN: 0005295313 *

Also Published As

Publication number Publication date
US20200069786A1 (en) 2020-03-05
US20220160854A1 (en) 2022-05-26
AU2019334261B2 (en) 2025-04-10
KR20210086610A (ko) 2021-07-08
EA202190669A1 (ru) 2021-06-03
GB201814362D0 (en) 2018-10-17
IL281220A (en) 2021-04-29
BR112021004075A2 (pt) 2021-05-25
MX2021002543A (es) 2021-08-11
CL2021000534A1 (es) 2021-09-24
US20210236611A1 (en) 2021-08-05
SG11202101881UA (en) 2021-03-30
CA3110923A1 (en) 2020-03-12
EP3847185A1 (en) 2021-07-14
CO2021004028A2 (es) 2021-06-21
JP2025069437A (ja) 2025-04-30
MA53544A (fr) 2021-07-14
WO2020048995A1 (en) 2020-03-12
CN113383009A (zh) 2021-09-10
AU2019334261A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP2025069437A (ja) ワクチン組成物を調製するためのプロセス
US11628211B2 (en) Vaccine
JP7642530B2 (ja) ペプチドワクチン
CN113330313B (zh) 免疫原性癌症筛选试验
EA051243B1 (ru) Пептидные вакцины
EA048432B1 (ru) Вакцина

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008